I'm a multi-disciplinary freelance journalist, copywriter, SEO content writer and developer, business blogger, social media manager and content marketing sage. I'm a seasoned professional with more than 20 years' experience creating and publishing high-quality content in multiple genres. My expertise includes most business, professional, medical, and niche markets. Visit my website (ernstPR.com) or email me at liz@ernstpr.com. All content containing my byline is registered with the U.S. Copyright Office and protected by plagiarism detection software.. © 2017; Liz Ernst. All rights reserved.

Silvina Pastrana, M.D.

Sylvina Pastrana, M.D.

Silvina Pastrana, M.D. is medical director of the Stem Cell Center Buenos Aires and Regentherapy Puerto Madero. Dr. Pastrana heads a staff of medical specialists in orthopedics, rheumatology, medical clinic and cosmetic surgery, performing procedures that incorporate stem cell therapies. Dr. Pastrana also serves as a staff surgeon for the Hospital Dr. Prof. Luis Güemes.

Dr. Pastrana received her medical degree at the Argentinian University of Buenos Aires and completed her residency at the Hospital Dr. Prof. Luis Güemes in Buenos Aires. She continued her  postgraduate studies in Spain while gaining knowledge about minimally invasive and percutaneous surgery.

Enrique Testart, M.D.

Enrique Testart, M.D.

Enrique Testart, M.D., Global Stem Cells Group’s Chief Medical Officer (CMO), is a surgeon specializing in child trauma microsurgery.

Dr. Testart is also a medical entrepreneur and founder of Consortia Innovas S.A. in Santiago, Chile, dedicated to consulting and clinical health management for clinical management firms and research and development-oriented planners in the latest treatments in regenerative medicine as they become available.

A native of Santiago, Chile, Dr. Testart’s medical studies took him all over the world, including orthopedics studies under the direction of Prof. Jean Paul Metaizeau, M.D. in France.

He is in charge of all Global Stem Cells Group divisions and programs in Chile, including patient recruitment through Cellgenic, medical training and certification through Stem Cell Training Inc., and everything related to the sale of equipment disposable through Adimarket.

stem cell medicine

Stem cell medicine is based on the concept that physicians can harness the body’s own reserves to heal itself, rather than relying exclusively on drugs or invasive surgical procedures. Stem cell medicine works by deals engineering human stem cells to replace or restore damaged or diseased organs or tissue, or establish normal function in them. While regenerative medicine primarily includes therapies a that utilize stem cells, the term is also used to describe therapies that use progenitor cells, used for many decades in the form of bone marrow transplants, as well as other cellular products such as platelet-rich plasma (PRP).

While both PRP and progenitor cells are widely used in clinical settings, stem cell therapies are still playing catch-up. PRP is used to treat orthopedic injuries and degenerative joint disease.

However, stem cells are in high demand worldwide. The burgeoning field of stem cell medicine is widely understood in a vague sort of way, but few people are aware that there are different kinds of stem cells. They can be derived from different tissue sources, harvested from the patient’s own body or donated. To help establish a better understanding of the stem cell landscape, we’ll start with some basic concepts.

Autologous vs. Allogenic Stem CellsProgenekine

Stem cell treatments are generally divided into two classes:

  • Autologous stem cells – collected from your own body, exclusively for your own use
  • allogeneic stem cells, harvested from another person (donor)

Current clinical trials involving both autologous and allogeneic therapies are taking place all over the world. These trials target a wide range of diseases and conditions, from heart disease to orthopedic conditions, to wound healing.

Autologous treatments using your own stem cells can be performed in the same operative session, which eliminates concerns over your body rejecting donor cells.  Your stem cells are extracted from your tissue, and reinjected back into your body targeting the area or organ that needs mending. This is a one-to-one therapy.

Allogeneic therapies use stem cells donated from another person. Before these cells can be put into a different human body than the one they came from, they must undergo extensive testing for diseases, and the cells are usually culture expanded in laboratories to achieve higher cell counts. Allogeneic therapies are performed under strict FDA guidelines, as these stem cells can eventually scale up in mass production, be stored and potentially distributed to millions of patients.

Stem Cell Types

stem cell medicineAdult stem cells (non-embryonic) are undifferentiated cells found throughout the body that multiply by cell division to replenish dying cells and regenerate damaged tissues.

Stem cells are acquired from various tissue sources, and each tissue source has different potentials for the cells to differentiate. The following information explains these tissue sources and corresponding type of stem cells:

Adult Stem Cells (ASC’s)
In recent decades researchers discovered that stem cells can be found in all adult tissues. These are called adult stem cells, and although they cannot differentiate into every type of cell like embryonic stem cells, they can differentiate into bone, cartilage and adipose (fat) tissue readily. The two most familiar sources of adult stem cells are bone marrow and adipose tissue. More than 2,000 clinical trials have been conducted worldwide using the various tissue sources of adult stem cells.

IPS Cells (induced pluripotent cells)
IPS cells come from adult cells. Their genetic code is biologically manipulated to become pluripotent, which means they can differentiate, or become any other type of cell. Because the genetic code of IPS cells has been altered, they carry a higher risk profile than both adult stem cells and embryonic stem cells.

Embryonic Stem Cells (ES)
Embryonic stem cells, first isolated in mouse embryos in 1981, are derived from the embryo of a human fetus. Controversy has pursued embryonic stem cell research since its inception, over of ethical and religious perceptions. Embryonic stem cells are currently used mainly for research and understanding how regenerative cells work.

Types of Adult Stem Cells

Adult stem cells can be isolated from bone marrow, adipose tissue, umbilical cord blood, peripheral blood, dental pump, and stem cell medicineother sources. Most recently, a large number of clinical trials are focusing on stem cells derived from bone marrow and adipose tissue.

Bone Marrow Stem Cells
Bone marrow stem cells were the first recognized form of adult stem cells in the body. Researchers found they could be used to help heal bone and to replace different cell types in the blood. They could also be used in cancer patients whose bone marrow was destroyed by radiation therapy or chemotherapy. Use of bone marrow stem cells is FDA approved under certain conditions.

The drawback with bone marrow stem cells is that they are difficult to extract and not abundant. In order to be used as a treatment, bone marrow stem cells must be expanded in culture in a lab. The FDA places this therapy in the category of a drug, and requires rigorous oversight and testing.

Adipose Derived Stem Cells
In 2001, researchers and plastic surgeons from the University of Pittsburgh discovered that human fat tissue is a very rich source of mesenchymal stem cells (MSCs),  multipotent stromal cells that can differentiate into a variety of cell types, and the findings were published in Tissue Engineering Journal. Upon publication, this discovery stirred quite an epiphany in the medical and scientific community—until then, adult MSCs were predominantly believed to be strictly a bone marrow product.



Adipose stem cells (pictured) harvested from body fat. (Photo: Genetic Engineering & Biotechnology News).

The discovery of abundant stem cell populations in body fat tissue changed everything the medical community thought it knew about stem cells overnight. Now, adipose stem cell therapies are driving the plastic and cosmetic surgery industries, and demand among patients keeps rising.

In 2001, researchers and plastic surgeons from the University of Pittsburgh discovered that human fat tissue is a very rich source of mesenchymal stem cells (MSCs),  multipotent stromal cells that can differentiate into a variety of cell types. When their findings were published in Tissue Engineering Journal, the discovery stirred quite an epiphany in the medical and scientific community—until then, adult MSCs were predominantly believed to be strictly a bone marrow product.


 Click on image to enlarge

Little did those researchers realize at the time that their discovery would revolutionize cosmetic surgery in less than a decade.

Adipose tissue offers distinct advantages over bone marrow tissue. Adipose fat is easier to extract than bone marrow, and the stem cell population contained in fat tissue is far more abundant than in bone marrow. One ounce of fat contains 300-500 times as many mesenchymal stem cells as an ounce of bone marrow. And unlike bone marrow, because of autologous adipose tissue’s copious stem cell count, most procedures using them do not require cells to be expanded in a lab, which means that most adipose stem cell therapies can be performed in the same operative procedure. Because bone marrow typically needs to be culture expanded for days in a lab before they can be re-injected back into a patient and adipose cells do not, there are plenty of advantages to adipose stem cell therapies.

adipose stem cell therapiesOver the past 10 years, plastic surgeons have established safe and convenient ways to remove fat and isolate the stem cells for use in cosmetic procedures. And since adipose stem cells are extracted and reintroduced to the patient’s own body, the risk of rejection that goes with donor stem cells is eliminated. Scores of ongoing clinical trials using adipose stem cells have already proven their safety and efficacy in a variety of applications. Anti-aging therapies using adipose stem cells, for instance, have grown exponentially in popularity.

adipose stem cell therapies

         BEFORE                              AFTER
       Cosmetic cell assisted fat transfer

As we age, cells become progressively damaged over time from sun, toxins in the environment, and the natural loss of moisture that keeps youthful skin full and wrinkle-free. Adipose stem cells work to regenerate and repair that damaged tissue, and adjunctive treatments can potentially slow down or reverse the aging process. Those cells possess a unique anti-aging effect by means of regenerating and repairing organs—including skin—damaged by environmental elements we are exposed to in our daily life, and by improving immune functions.

This discovery has created an international demand for stem cell anti-aging therapies, which since these procedures are non-invasive (no surgery involved), make for a faster recovery and significantly less downtime for patients. Many patients and physicians feel that adipose stem cells also create a more natural appearance for recipients than traditional cosmetic surgery procedures. Some cosmetic stem cell physicians have taken it up a notch with cell assisted fat transfer, in which autologous adipose-derived (stromal) stem cells are used in combination with lipoinjection for even softer, more natural results.

Here’s how it works: a stromal vascular fraction (SVF) containing ASCs is freshly isolated from half of the aspirated fat and recombined with the other half. This process converts relatively ASC-poor aspirated fat to ASC-rich fat, reducing the potential for postoperative atrophy of injected fat to a minimal level, which clinical trials have found does not change substantially after two months.

Adipose Tissue as a Regenerative Therapy

While adipose tissue is a definitive source of stem cells, what if you don’t need to isolate or separate the stem cells to benefit from their regenerative powers?

adipose stem cell therapies

Radiation to treat a tumor severely effected this boy’s facial growth and development, caused significant facial asymmetry and left a large cosmetic defect on the side of his head. Fat grafting surgery restored his appearance to that of any healthy, happy, 14-year-old.

Plastic surgeons have known for years that fat grafting itself, without extracting the stem cells, has regenerative properties. Cosmetic surgeons have developed safe and predictable techniques for fat grafting and have documented the regenerative effects of fat grafting in different tissues, for a variety of conditions and diseases. Adipose stem cell rich fat grafting has been documented to reverse radiation tissue damage, something that was considered irreversible until recently. Current clinical studies are documenting the regenerative effects of fat grafting in areas no one suspected, such as autoimmune diseases and degenerative joint disease. Unlike bone marrow tissue, adipose tissue is easy to extract, it’s abundant, and it’s effective in ways researchers have only begun to discover. Cell-assisted fat grafting serves a valuable role helping people with disfiguring injuries and birth defects. Plastic surgeons

Plastic surgeons have acquired decades of experience in harvesting and refining adipose tissue for treating patients. Thanks to the remarkable level of expertise they have developed with adipose tissue, experts now play a leading role in developing its evolving regenerative applications. Regenerative medicine is changing the landscape of cosmetic and reconstructive surgery, and aesthetic medicine—and it keeps getting better!


Harvard medical

George Q. Daley, MD, PhD, Harvard Medical School’s newly appointed dean, led dozens of international colleagues in developing ethical guidelines for stem cell research. On March 9, 2009, President Barack H. Obama issued Executive Order 13505: Removing Barriers to Responsible Scientific Research involving Human Stem Cells, stating that the Secretary of Health and Human Services, through the Director of the National Institute of Health (NIH), may support and conduct responsible, scientifically worthy human stem cell research, including human embryonic stem cell (hESC) research, to the extent permitted by law. Internal NIH policies and procedures, consistent with Executive Order 13505 and these Guidelines, govern the conduct of intramural NIH stem cell research.

A prominent stem cell researcher has been named the new dean of Harvard Medical School, the university announced August 9th

George Q. Daley, MD, PhD, who led dozens of international colleagues to unite around ethical guidelines for stem cell research, isHarvard Medical taking on a new challenge—unifying the powerful hospitals that train Harvard’s medical students.

Daley will assume the position effective Jan. 1, 2017, succeeding Jeffrey Flier, MD, who stepped down July 31st. Barbara McNeil, MD, the founding head of the Department of Health Care Policy at Harvard Medical School, is filling the position in the interim.

The internationally recognized leader in stem cell science and cancer biology and a longtime member of the Harvard Medical School (HMS) faculty whose work includes the fields of basic science and clinical medicine, Daley was the driving force behind creating international guidelines around first, human embryonic stem cell research, and then the clinical application of stem cells, according to Nancy Witty, CEO of the International Society for Stem Cell Research (ISSCR).

Daley, who cofounded the organization, counseled two dozen scientists through the sensitive ethical discussions involved in establishing stem cell research guidelines, utilized additional input from 60 groups around the world to construct the guidelines which were first published by the National Institute of Health in 2009.

“That’s a very difficult task,” Witty said. “It takes a tremendous amount of diplomacy.” Harvard Medical

Daley is working to adapt insights in stem cell research to improved therapies for genetic and malignant diseases. Important research contributions from his laboratory at Harvard-affiliated Boston Children’s Hospital include the development of customized stem cells to treat genetic immune deficiency in a mouse model (in collaboration with Rudolf Jaenisch, a Professor of Biology at MIT); the differentiation of germ cells from embryonic stem cells (cited as a “Top Ten Breakthrough” by Science magazine in 2003), and the generation of disease-specific pluripotent stem cells by direct reprogramming of human fibroblasts (cited in the “Breakthrough of the Year” issue of Science magazine in 2008).

As a graduate student working with Nobel laureate Dr. David Baltimore, Daley demonstrated that the BCR/ABL oncogene induces chronic myeloid leukemia (CML) in a mouse model, which validated BCR/ABL as a target for drug blockade and encouraged the development of imatinib (GleevecTM; Novartis), a revolutionary magic-bullet chemotherapy that induces remissions in virtually every CML patient. Dr. Daley’s recent studies have clarified mechanisms of Gleevec resistance and informed novel combination chemotherapeutic regimens.

Daley has spent his entire career in Cambridge and Boston, earning a medical degree from Harvard and a PhD in biology from MIT. As Dean of Harvard Med School, Daley’s achievements in stem cell research is expected to shine a distinguished light on the stem cell industry.

Although the position of dean of Harvard Med may be one of the most prominent roles in medicine, the position is not as powerful it might seem: Harvard Med does not directly oversee any hospitals. Instead it relies on 15 affiliated hospitals and clinical sites, which have historically operated as separate, competitive bailiwicks, to train its students and postdoctoral fellows, and support its researchers. Only 151 of the nearly 12,000 people who call themselves Harvard Medical faculty actually work directly for Harvard in its 10 basic science departments.

Daley sees his new position as a congregator who “builds bridges among the institutions” —heavyweight research institutions such as Brigham and Women’s, Massachusetts General, and Boston Children’s hospitals. Persuasiveness, rather than power, is all that Daley says is needed to achieve an alliance.

Daley’s predecessor, Flier, says he spent a full 30 percent to 40 percent of his time as dean trying to build relationships with and coordinate Harvard’s affiliated hospitals and clinics, a challenge Daley says he’s up to. He has a head start in building those relationships through the many positions he has held around Boston’s biomedical community, including chief resident at Mass. General

“My vision is one of increasing connectivity across the community,” Daley says.

Currently a professor of biological chemistry and molecular pharmacology at Harvard Medical School and director of the stem cell transplantation program at Boston Children’s and Dana-Farber Cancer Institute, Daley sees areas of common interest, such as immuno-oncology, which harnesses the body’s own immune system against cancer cells, where the hospitals can work more closely together.

Described by colleagues as a natural leader, Daley recently led an effort to coordinate big-name scientists across several institutions on a collaborative grant to compare two types of stem cells—just one example of how he earned a reputation; he knows how to get different groups talking together in a constructive way.

He also says he wants Harvard Medical’s faculty, students, and staff to reflect the global community the school intends to serve, and that he promotes diversity in hiring for his 30-person lab.

Daley has a keen interest in sickle-cell anemia, which affects people of African descent, including African Americans, and he believes the federal government should invest in a moonshot effort to cure the disease.

Daley plans to continue teaching molecular medicine at Harvard Med after assuming his position as dean. He also plans to spend one day per week in his lab researching blood stem cells.

“It’s important for a dean to remain relevant by continuing to publish papers,” Daley says. “Plus, I just love science.”

Among his priorities is raising money. Despite its worldwide reputation, and its relative influence when it comes to landing federal grants, Harvard Med has seen annual deficits of between $31 million and $45 million for three consecutive years. Suggestions are being made for Harvard to rename its medical school in return for a billion-dollar donation. Daley only says that the idea would be worth considering down the road.

With opportunities for federal grants in decline, Daley says he sees an opportunity to bring in money from corporate partnerships.

For the stem cell research and medical community, Daley’s appointment as dean of Harvard Med is a fitting step toward validating regenerative medicine’s place as an authoritative leader in the future of medicine—one that’s been a long time coming.

Learn more about Dr. Daley here.


Alfredo Hoyos, M.D.


Alfredo Hoyos, M.D., Global Stem Cells Group’s chief scientific officer (CSO), is a renowned  board-certified plastic surgeon from Bogotá, Colombia. Dr. Hoyos earned his medical degree at El Rosario University in Bogotá and performed his residency in plastic surgery at the Rosario – Saint Joseph Hospital, also in Bogotá.

The inventor of High Definition Liposculpture (HDL), Dynamic Definition Lipoplasty (4D), and other advanced body contouring techniques, Dr. Hoyos has been an innovator since early in his career, embracing the potential of stem cells early on. He is well known for his surgical skills, and recognizing new opportunities to advance the efficacy of health care treatments. One of the most promising breakthroughs toward that end is the acceleration of stem cell discoveries over the past 20 years.

Dr. Hoyos recognized the potential of these remarkable, undifferentiated cells, capable of  self-reinvention when called upon to take on the functions of other cells in the body when needed, giving rise to a new field of vision for the future of surgical and aesthetic protocols, and the future of medicine altogether. Dr. Hoyos adapts the healing  and restorative capabilities of stem cells  to the aesthetic procedures he performs—including fat grafting and fat transfer—and  has successfully performed assisted stem cell fat transfer procedures for patients looking to restore volume in the facial area that is lost in the natural aging process.

Dr. Hoyos continues to identify new opportunities in innovative medical technology that can improve the quality of patients’ lives.  After adopting and mastering  Vaser ultrasonic liposuction technology, also known as liposelection (an alternative to traditional liposuction) he later developed the Vaser Hi Definition Lipoplasty (VHD) procedure.

Dr. Hoyos founded Stem Lab, a biotechnology company based in Bogotá, to further the development of stromal stem cells derived from adipose tissue. He continues to develop and refine these techniques, while exploring new applications for HD and other emerging technologies  in the field of aesthetic  surgery.

He is an accomplished sculptor, painter, medical book illustrator and author. of several books focusing on high definition body sculpting and advanced lipoplasty techniques. Dr. Hoyos is certified by the Colombian Society of Plastic Surgery, (SCCP) and the  International Confederation of Plastic Reconstructive and Aesthetic Surgery (IPRAS).

total solution

MIAMI, Aug. 23, 2016 – Global Stem Cells Group and its subsidiary Adimarket announce a collaborative agreement with South Korean biomedical and lab equipment manufacturer N-Biotek to offer the Total Solution highly manipulated stem cell culture expansion lab, complete with equipment, training, facilities, stem cell processing center, clean rooms, project plan and more- a total turnkey lab solution for emerging stem cell businesses and industry professionals.

The announcement marks a new chapter in GSCG’s ongoing expansion, and commitment to bring stem cell therapies to

total solution

Physicians at work in Total Solution turnkey stem cell lab

patients worldwide. By joining with N-Biotek to bring this exceptional, ready-to-go stem cell culture expansion lab to scientists and institutions throughout North and South America, GSCG is facilitating research and development in the critical need areas of highly manipulated stem cell protocols and cryopreservation of cell colonies.

Until now, Admarket has been GSCG’s online marketplace for quality regenerative medicine equipment and supplies for physicians and health care professionals, offering basic tools and products to facilitate in-office stem cell procedures. However, through N-Biotek, Adimarket now offers the Total Solution labs and all the accoutrements. From planning to building the facility, to training and consultation, Total Solution users are equipped in every way possible to walk in and begin using their fully-equipped biotechnology lab in short order.

total solution

Total Solutions clean room and stem cell lab equipment

The collaboration with N-Biotek means GSCG and Adimarket can create a stem cell processing center for researchers who require more advanced lab environments to conduct complex research and develop processes and procedures for the fast-growing stem cell market.

The Stem Cell Total Solution is a comprehensive business solution that provides the entire stem cell processing system-from business planning to business procedures, a state-of-the-art cellular processing facility with bio safety clean rooms for stem cell processing, quality control rooms, core technology, cutting-edge equipment, installation, training-everything needed to launch a stem cell business or a enhance a medical research practice in a short period of time.

N-Biotek has been providing its Stem Cell Total Solution labs and consulting services, as well as stem cell processing technology management services, to universities, research centers, physicians and biotechnology enterprises in South Korea, China, Japan and Vietnam for years.

total solutionHighly manipulated stem cells are critical to biotechnology researchers in order to advance both fundamental knowledge of the undifferentiated cells that have the remarkable potential to develop into many different cell types in the body during early life and growth, and to find ways to use them to treat medical and cosmetic conditions non-invasively. Additionally, in many tissues, stem cells serve as a sort of internal repair system, dividing essentially without limit to replenish damaged and dead cells for as long as the person or animal they inhabit is alive.

When a stem cell divides, each new cell has the potential to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell, and this allows researchers to manipulate these extraordinary reconstructionist micro-organisms to differentiate into other cell types that can be used to treat disease and injuries affecting parts of the body from which they did not originate. For instance, a stem cell harvested from body fat can be manipulated to take on the functions of a pancreatic cell, a heart cell or a retina cell. Researchers see unlimited potential in their ability to heal wounds, cure diseases, and even prevent birth defects.

total solution“Non-destructive manipulation of stem cells in a precise environment is key to facilitating discoveries within the biology and medical research communities,” says Benito Novas, CEO of Global Stem Cells Group. “Our collaboration with N-Biotek to deliver the Total Solution for highly manipulated stem cell culture expansion labs to emerging stem cell scientists is the next phase in GSCG’s mission to fulfill our promise of making stem cell-based therapies available to patients everywhere.

“Stem cell manipulation resulting in cells that possess the characteristics necessary for successful differentiation, transplantation, and engraftment is critical to discovering new methods for treating illness and impairments,” Novas says.

Global Stem Cells Group and N-Biotek provide Total Solution users with everything they need to culture, expand and cryopreserve stem cells right away. Each system comes with manufacture patents and full certification. All products and total solutionequipment is made to comply with, or exceed standards required for CE Certification.

N-Biotek is the only company that builds the entire stem cell processing system for clients ready to begin a stem cell business, or establish a lab facility to enhance their medical or research practice.

To learn more about the N-Biotek Stem Cell Total Solution, visit the Global Stem Cells Group website at  or the AdiMarket website, email bnovas@stemcellsgroup.com, or call 305-560-5337.

About Global Stem Cells Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

About Adimarket:
Adimarket, Inc., a subsidiary of Global Stem Cells Group, is a cost-competitive online marketplace for quality regenerative medicine equipment and supplies for physicians and health care professionals. Adimarket was founded to provide physicians and other health care professionals the tools they need to practice regenerative medicine in a medical office setting.

Motivated by a firm belief in the positive impact the practice of stem cell medicine can have when dispensed in a doctor’s office, Adimarket provides physicians with the tools they need to provide patients with cutting edge treatments. Adimarket’s experienced customer service representatives provide valuable guidance and advice regarding products relevant to individual practices.

About N-Biotek:
Since 1982, N-Biotek has been the leading manufacturer of biomedical and lab equipment worldwide. The Stem Cell Total Solution lab is a culmination of years of dedication to establish compact and customized products in developing the Handy Lab-a personal lab for medical, scientific and university professionals. N-Biotek is known for its high quality, uniquely designed biomedical products and equipment and competitive pricing. Over the years, the company’s products have earned an array of patents, and all meet international standards including CE, ETL, ISO and GMP. N-Biotek also offers real-time monitoring through IT technology.

Since 2010, N-Biotek has expanded significantly, starting new businesses including a stem cell processing system and biological clean room, GMP consulting, validation services and health care services for foreign consumers in order to maintain its lead in the life science field.

To view this press release live online, please click here


Stem cell training Madrid

 Global Stem Cells Group has announced a stem cell training course in Madrid, Spain, to be held Dec. 6 – 7, 2016, in collaboration with Javier Garcia Alonso, MD and Clinica Castellana Norte.

stem cell training Madrid

Physicians at a recent stem cell training course

MIAMI, Aug. 16, 2016—Global Stem Cells Group and Stem Cell Training, Inc. will host a stem cell training course in Madrid, Dec. 6-7, 2016, in collaboration with Javier Garcia Alonso, MD of Clinica Castellana Norte in Madrid. Garcia Alonso is a specialist in plastic, reconstructive and aesthetic surgery.

The stem cell training course, available to qualified physicians, will focus on stem cell protocols in cosmetic, anti-aging, and aesthetic procedures.

The Adipose and Bone Marrow Stem Cell Training Course was developed for physicians and high-level practitioners to learn the process through a two-day, intensive, hands-on training program to arm participating physicians with clinical protocols and state-of-the-art techniques for isolating and re-integrating adipose- and bone marrow-derived stem cells. When used in aesthetic medicine therapies, patients walk away with more natural-appearing augmentation and enjoy a faster recovery period with little to no downtime.

Garcia Alonso will host and participate in training qualified physicians in stem cell harvesting, isolating and re-integration stem cell training course in Barcelonatechniques and protocols, during which stem cells are harvested from the patient’s own body and redistributed to areas of the body receiving augmentation.

Stem cell therapy is a promising treatment for facial rejuvenation and soft tissue augmentation because there are no incisional scars or complications associated with foreign materials. Demand for stem cell procedures s high worldwide—these effective procedures that do not involve going under the knife are driving the growth of stem cell protocols in the cosmetic industry, as more patients request new technologies that are less invasive than ever before.

Breast augmentatistem cell training course in Barcelonaon, abdominoplasty, facelifts and liposuction continue to feature in the top most requested procedures for many clinics, surgeons say an increasing number of patients are seeking a more natural look with a quicker recovery time, according to Benito Novas, CEO of Global Stem Cells Group. In fact, non-surgical cosmetic procedures have grown exponentially over the past five years, and the trend is expected to continue to rise.

Surgeons are also seeing more diverClinica Castellana Norte.sity when it comes to the type of procedures requested, including buttock enhancements, hair transplantation and anti-aging procedures on hands.

“Patients are demanding procedures that are quick, easy, and provide a fast recovery with minimal downtime,” Novas says. “Stem cells provide the ability to rejuvenate and heal, making them a natural treatment for cosmetic and anti-aging applications.”

The stem cell training course will be offered through Global Stem Cells Group affiliate Stem Cell Training, Inc.

To learn more, visit the Global Stem Cells Group website, or the Stem Cell Training website, email bnovas(at)regenestem(dot)com, or call +1 305 560 5337.

About Global Stem Cell Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

About Stem Cell Training, Inc.:

Stem Cell Training, Inc. is a multi-disciplinary company offering coursework and training in 35 cities worldwide. The coursework offered focuses on minimally invasive techniques for harvesting stem cells from adipose tissue, bone marrow and platelet-rich plasma. By equipping physicians with these techniques, the goal is to enable them to return to their practices, better able to apply these techniques in patient treatments.

About Clinica Castellana Norte:

Clinica Castellana Norte in Madrid of
fers a comprehensive range of aesthetic and reconstructive procedures, from dietary advice to state-of-the-art stem cell therapies for cosmetic procedures. Clinica Castellana Norte operates under the highest quality standards, not only in medical and aesthetic treatments offered, but throughout the administrative process, ensuring privacy. Clinica Director Javier Garcia Alonso, M.D., is a member of the Spanish Society of Plastic Reconstructive and Aesthetic Surgery (SECPRE), and a member of the International Society of Plastic, Reconstructive and Aesthetic Surgery (IPRAS).

To view this press release live online, click here